RESULTS
Demographic and baseline disease characteristics are shown in Table 1. A total of 21 patients aged 21 to 72 years received HP/TAZ; however, 57% of patients completed all 24 weeks of treatment. 52% of patients had failed monotherapy with Class I, II, and III topical corticosteroids. Among 21 patients, 5 (24%) achieved a ppPGA of 0 or 1 after 24 weeks or LOCF (primary endpoint). Figure 1 shows improvement of ppPGA following 12 weeks of treatment with HP/TAZ. The mean ppPGA significantly decreased from baseline (3.57) to week 24/LOCF (2.38) as shown in Figure 2 (P<0.001). Median ppPGA at baseline and week 24/ LOCF were 3.0 (Interquartile Range [IQR] 1.0) and 2.0 (IQR 1.0), respectively, with a difference of 1.0 (IQR= 1.0; CI 95%= [1.0; 2.0]; P<.001). Overall, 62% were moderately or very satisfied with treatment (data not shown).
Most frequently reported treatment-related adverse events were application site pruritis (14%), stinging (5%), and burning (10%) with none requiring discontinuation. There were no serious adverse events reported.
Most frequently reported treatment-related adverse events were application site pruritis (14%), stinging (5%), and burning (10%) with none requiring discontinuation. There were no serious adverse events reported.
DISCUSSION
HP/TAZ lotion significantly improved signs, symptoms, and
severity of moderate-to-severe palmoplantar plaque-type
